Loading…
  • Therapie der Zukunft: we fight your cancer

PSMA therapy improves health-related quality of life in patients with prostate cancer

¹⁷⁷Lu-PSMA therapy improves health-related quality of life in patients with mCRPC

On Friday, 17 September 2021, Novartis announced further positive findings from the VISION trial: 177Lu-PSMA-617 therapy delays worsening of physical functioning and the onset of pain symptoms in patients with mCRPC. Hence, beyond extending overall survival and progress-free period, this Breakthrough Therapy also improves health-related quality of life. Read more